Mitsubishi Tanabe Pharma
Mitsubishi Tanabe Pharma Corporation, often referred to as MTPC, is a prominent player in the global pharmaceutical industry, headquartered in Japan. Established in 1678, the company has evolved significantly, focusing on innovative drug development and therapeutic solutions primarily in the fields of neurology, immunology, and diabetes care. With a strong presence in Japan, North America, and Europe, Mitsubishi Tanabe Pharma is renowned for its unique core products, including treatments for multiple sclerosis and other chronic conditions. The company has achieved notable milestones, such as the successful launch of its flagship drug, which has positioned it as a leader in the biopharmaceutical market. Committed to advancing healthcare, Mitsubishi Tanabe Pharma continues to make significant contributions to patient well-being through its research and development initiatives.
DitchCarbon Score
How does Mitsubishi Tanabe Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mitsubishi Tanabe Pharma's score of 40 is higher than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Mitsubishi Tanabe Pharma's reported carbon emissions
In 2023, Mitsubishi Tanabe Pharma reported total greenhouse gas emissions of approximately 700,900,000 kg CO2e, with Scope 1 emissions at about 18,700,000 kg CO2e and Scope 2 emissions at around 36,300,000 kg CO2e. The company has set ambitious long-term climate commitments, aiming for net-zero emissions by 2050. Specifically, they target a 45% reduction in Scope 1 and Scope 2 emissions by 2030, compared to fiscal 2019 levels. Over the years, Mitsubishi Tanabe Pharma has demonstrated a commitment to reducing its carbon footprint. For instance, in 2022, their total emissions were approximately 700,900,000 kg CO2e, with Scope 1 and 2 emissions at about 20,300,000 kg CO2e and 37,900,000 kg CO2e, respectively. This reflects a proactive approach to managing emissions across their operations. The company’s reduction targets encompass all domestic and overseas group companies, highlighting a comprehensive strategy to tackle climate change. Mitsubishi Tanabe Pharma's initiatives align with industry standards for climate action, reinforcing their commitment to sustainability and environmental responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 35,400,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 71,800,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 0,000,000 | 0,000,000 | 0,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mitsubishi Tanabe Pharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
